| Thyroid remnant ablation in patients with papillary cancer: a comparison of low, moderate, and high activities of radioiodine. | |
| | |
MedLine Citation:
|
PMID: 19247212 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: The consensus about optimal activities of I-131 for thyroid remnant ablation has not yet been achieved. The aim of this study was to compare ablation rates obtained with different I-131 activities. PATIENTS AND METHODS: The study included 466 patients divided into four groups according to I-131 activities given after total thyroidectomy for papillary thyroid cancer: group A [168 patients who received 888 MBq (24 mCi)], group B [125 patients who received 1480 MBq (40 mCi)], group C [65 patients who received 1850 MBq (50 mCi)], and group D [108 patients who received 4440 MBq (120 mCi)]. Ablation outcome was assessed by whole-body scan in hypothyroid state 6-9 months after ablation and finally 18-21 months after the treatment. RESULTS: The rate of successful ablation was similar in the group of patients who received 24 and 40 mCi (75 and 71.2%, respectively). The higher rate of ablation was achieved in the groups treated with 50 and 120 mCi of radioiodine (87.69 and 90.74%, respectively). The ablation rates at the first follow-up examinations (59.5, 67.2, 73.9, 80.6%) were lower than at second control study (75.0, 71.2, 87.7, 90.7%) in all groups. Time required for thyroid remnant ablation seems to be >or=18 months. CONCLUSION: Our study indicates that activity of 50 mCi seems to be optimal to achieve a successful ablation rate (approximately 90%). Low I-131 activities are acceptable for lower risk patients because of satisfactory ablation rate (>70%), lower expense, and minimal radiation burden to patients as well as lower radiation exposure to clinical staff. The ablative use of high activities seems neither justified nor optimized. |
| | |
Authors:
|
Sanja Kusacic Kuna; Tatjana Samardzic; Vanja Tesic; Mario Medvedec; Krunoslav Kuna; Irena Bracic; Marija Despot; Damir Dodig |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Nuclear medicine communications Volume: 30 ISSN: 0143-3636 ISO Abbreviation: Nucl Med Commun Publication Date: 2009 Apr |
Date Detail:
|
Created Date: 2009-04-09 Completed Date: 2009-05-01 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8201017 Medline TA: Nucl Med Commun Country: England |
Other Details:
|
Languages: eng Pagination: 263-9 Citation Subset: IM |
Affiliation:
|
Clinical Department of Nuclear Medicine and Radiation Protection, Clinical Hospital Centre Zagreb, Zagreb, Croatia. sanja.kusacickuna@gmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Carcinoma, Papillary / radionuclide imaging, radiotherapy*, surgery* Female Humans Iodine Radioisotopes / therapeutic use* Male Middle Aged Radiopharmaceuticals / therapeutic use Thyroid Gland / radionuclide imaging, surgery* Thyroid Neoplasms / radionuclide imaging, radiotherapy*, surgery* Thyroidectomy Thyrotropin / blood Treatment Outcome Whole Body Imaging Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Iodine Radioisotopes; 0/Radiopharmaceuticals; 9002-71-5/Thyrotropin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid.
Next Document: Ras dependent paracrine secretion of osteopontin by Nf1+/- osteoblasts promote osteoclast activation...